Takeda Type II diabetes drug shown useful in late-stage trial

09/13/2005 | Wall Street Journal, The

Researchers report that Takeda Pharmaceuticals' Actos proved effective in a late-stage trial in reducing the risk of fatal or serious conditions associated with Type II diabetes. In conjunction with Eli Lilly, Takeda has been developing the drug, which the companies said reduced the combined risk of heart attacks, strokes and death by 16%.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ